DDInter1652 DDInter1926
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy [FDA label]. Previously, this drug was indicated only for patients with 17p gene deletion .
Venetoclax {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Venetoclax {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secobarbital
Venetoclax {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Venetoclax {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Venetoclax {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Venetoclax may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Venetoclax may lead to a major life threatening interaction when taken with Atazanavir
Venetoclax may lead to a major life threatening interaction when taken with Lorlatinib